Trillium Therapeutics completes US$55.2 million public offering

Date Closed: 4/7/2015

Value: US$55.2 million

On April 7, 2015, Trillium Therapeutics Inc. (Trillium) completed its underwritten public offering of common shares (Common Shares) and Series II non-voting convertible first preferred shares (Series II Preferred Shares) in the United States. Pursuant to the offering, Trillium sold 1,750,754 Common Shares and 1,077,605 Series II Preferred Shares in each case at a price of US$19.50 per share. The offering included 228,359 Common Shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. The gross proceeds to Trillium from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately US$55.2 million.  

Trillium, headquartered in Toronto, Ontario, is an immuno-oncology company developing therapies for the treatment of cancer.

BLG represented Trillium in Canada with a team led by Jay Lefton and Manoj Pundit that included Habeeb Syed and Linda Tu (Corporate and Securities) and Daniel Lang (Tax).